Pharmadrug Inc. (TSE:PHRX) has released an update.
PharmaDrug Inc. has announced that its majority-owned subsidiary, Sairiyo Therapeutics, has filed for Phase 1 clinical trial approval in Australia for their patented drug, PD-001, targeting infectious diseases and cancer. The drug, a reformulated version of cepharanthine, is expected to offer improved oral bioavailability over existing treatments and could benefit from Australian R&D tax incentives. Following the study, PharmaDrug plans to pursue FDA trials in the United States.
For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.
